Novel microfluidic development of pH-responsive hybrid liposomes: in vitro and in vivo assessment for enhanced wound healing

Wound healing is a complex biological process crucial for tissue repair, especially in chronic wounds where healing is impaired. Liposomes have emerged as promising vehicles for delivering therapeutics to facilitate wound repair. Liposomes have been explored as effective carriers for therapeutic agents. However, traditional methods of liposome preparation face significant challenges, particularly in achieving consistent stability and precise control over drug encapsulation and release. This study addresses these challenges by pioneering the development of Hybrid Liposomes (HLPs) using microfluidic technology, which provides more controlled characteristics through precisely managed formulation parameters. Notably, the formation of Polydopamine (PDA) polymer within HLPs facilitates pH-responsive drug release, making them well-suited for acidic wound environments. Furthermore, surface modification with Folic Acid (FA) enhances cellular interaction with the HLPs. In vitro and in vivo studies demonstrate the efficacy of HLPs loaded with Hyaluronic Acid (HA) or Phenytoin (PHT) in promoting wound healing. Microfluidics optimizes the stability of HLPs over 90 days, underscoring their potential as a potent, antibiotic-free drug delivery system. In conclusion, this research advances the understanding of microfluidic optimization for HLPs, offering cutting-edge drug delivery systems. The transformative potential of targeted HLPs through microfluidics holds promise for revolutionizing wound healing and inspires optimism for effective therapeutic interventions.